Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 8.6% – Should You Sell?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) fell 8.6% during mid-day trading on Wednesday . The stock traded as low as $30.16 and last traded at $30.16. 33,490 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 382,301 shares. The stock had previously closed at $32.99.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wedbush restated an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday. TD Cowen assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Finally, Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Price Performance

The business’s 50-day moving average is $25.47 and its two-hundred day moving average is $25.75. The firm has a market cap of $1.80 billion, a P/E ratio of -5.23 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Ikarian Capital LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $6,574,000. Jain Global LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,774,000. Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,772,000. Boothbay Fund Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,204,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at approximately $100,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.